Facebook Twitter LinkedIn Google Plus RSS

Soligenix treatment chosen for NIH accelerator program

By ,
Soligenix Inc. has been selected by the National Institutes of Health has selected for its Commercialization Accelerator Program.
Soligenix Inc. has been selected by the National Institutes of Health has selected for its Commercialization Accelerator Program. - ()

The National Institutes of Health has selected Soligenix Inc. for its Commercialization Accelerator Program, the Princeton-based biopharmaceutical company announced Thursday.

Soligenix also was chosen for NIH’s Commercialization Transition Track, which provides technical assistance to companies so that they may advance products to market.

The SGX942 development program, for which Soligenix was selected, is for treatment of oral mucositis in neck and head cancer patients receiving chemoradiation treatment.

The company applied for the program as part of a $1.5 million Phase II Small Business Innovation Research/Small Business Technology Transfer grant from NIH.

Soligenix is working to advance SGX942 with a Phase 3 clinical trial with top-line results anticipated for the latter half of next year.

More From This Industry

Jessica Perry

Jessica Perry


Jessica is the Web Editor for NJBIZ. You can reach her at jperry@njbiz.com.

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close